- Report
- October 2023
- 145 Pages
Global
From €3006EUR$3,150USD£2,519GBP
- Report
- May 2023
- 147 Pages
Global
From €4723EUR$4,949USD£3,957GBP
- Report
- May 2023
- 140 Pages
Global
From €4723EUR$4,949USD£3,957GBP
- Report
- December 2023
- 250 Pages
Global
€4767EUR$4,995USD£3,994GBP
- Report
- December 2023
- 271 Pages
Global
€4767EUR$4,995USD£3,994GBP
- Report
- January 2020
- 40 Pages
Saudi Arabia
From €1432EUR$1,500USD£1,199GBP
- Report
- January 2020
- 40 Pages
Japan
From €1432EUR$1,500USD£1,199GBP
- Report
- January 2020
- 40 Pages
China
From €1432EUR$1,500USD£1,199GBP
- Report
- September 2020
- 700 Pages
Global
From €4676EUR$4,900USD£3,918GBP
- Report
- August 2023
- 124 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- March 2024
- 132 Pages
Global
From €907EUR$950USD£760GBP
From €123EUR$129USD£103GBP
- Report
- September 2022
- 274 Pages
Global
From €3407EUR$3,570USD£2,855GBP
- Report
- July 2022
- 315 Pages
Global
From €3665EUR$3,840USD£3,071GBP
- Book
- June 2018
- 368 Pages
- Book
- November 2015
- 776 Pages
- Book
- August 2014
- 240 Pages
- Book
- January 2018
- 176 Pages
- Book
- January 2018
- 272 Pages
- Book
- February 2016
- 384 Pages

The iPS Cell market is a rapidly growing sector within the pharmaceutical industry. It is based on the use of induced pluripotent stem cells (iPSCs) to develop treatments for a variety of diseases. iPSCs are derived from adult cells, such as skin or blood cells, and are reprogrammed to become pluripotent stem cells. These cells can then be used to create a variety of cell types, such as neurons, heart cells, and liver cells, which can be used to study diseases and develop treatments.
The iPS Cell market is driven by the increasing demand for personalized medicine, as well as the potential for iPSCs to be used in regenerative medicine. Additionally, the use of iPSCs in drug discovery and development is becoming increasingly popular, as it allows for the testing of drugs on human cells in a laboratory setting.
Some of the major players in the iPS Cell market include Cellular Dynamics International, Takara Bio, ReproCELL, and Axol Bioscience. Additionally, a number of biotechnology companies, such as Novocell and Pluristem, are also developing iPSC-based treatments. Show Less Read more